Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for neutropenia prevention in pediatric cancer
NCT04547829Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Sun Yat-sen University. Primary endpoint: safety of PEG-rhG-CSF in the prevention of neutropenia at 6 weeks. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04547829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547829.